The idea of seeing a Woolly Mammoth walk the earth again has moved from the pages of science fiction into serious laboratory research. Colossal Biosciences, a biotechnology company co-founded by geneticist George Church and entrepreneur Ben Lamm, has set an aggressive deadline to achieve this. They aim to have their first mammoth-hybrid calves born by 2027 or 2028. Recent scientific milestones suggest this timeline remains plausible.
For years, the biggest hurdle in de-extinction was not just finding ancient DNA, but creating the right biological building blocks to use it. In a major update to their roadmap, Colossal Biosciences announced a massive breakthrough in March 2024. Their team successfully derived induced pluripotent stem cells (iPSCs) from Asian elephants.
This is a critical development for several specific reasons:
It is important to understand that Colossal is not cloning a mammoth from frozen cells. DNA degrades over thousands of years, meaning a perfect clone is impossible. Instead, they are using CRISPR gene-editing technology to edit the genome of the Asian elephant.
The Asian elephant shares 99.6% of its DNA with the Woolly Mammoth. The roadmap involves inserting specific mammoth traits into the elephant genome to create a cold-resistant hybrid.
The scientists are targeting roughly 50 to 60 specific genes that define what makes a mammoth a mammoth. These edits focus on survival in the Arctic tundra:
The target date of 2027 represents the birth of the first calf, but the biological clock of an elephant makes this a tight schedule. The gestation period for an elephant is approximately 22 months, the longest of any land mammal.
To hit a 2027 or 2028 birth date, a viable embryo must be implanted into a surrogate relatively soon. Colossal operates with two parallel tracks for gestation:
Critics often ask why money is being spent on de-extinction rather than conservation. Colossal argues that the two are linked. The return of the mammoth is not just for tourism or curiosity; it is a tool for “ecosystem engineering.”
The focus is on the “Mammoth Steppe,” a once-vibrant ecosystem in the Arctic. Currently, the Arctic tundra is mossy and forested. In the past, mammoths trampled trees and disturbed the soil, which encouraged the growth of grasslands.
Restoring this grassland ecosystem could have measurable climate benefits:
While the Woolly Mammoth is the flagship project, the roadmap extends to other species. The technologies developed for the mammoth are being applied elsewhere.
The roadmap to 2027 is ambitious. It relies on biology cooperating with technology at every turn. However, with the successful creation of elephant stem cells, the theoretical door has been unlocked. The team at Colossal Biosciences has moved from asking “if” this can be done to refining exactly “how” it will happen.
Is the animal going to be 100% Mammoth? No. It will be a functional mammoth, scientifically described as a cold-resistant Asian elephant with mammoth traits. It will look and behave like a mammoth, but its core DNA is Asian elephant.
Where will the mammoths live? The long-term goal is to release them into the Arctic region. Pleistocene Park, a scientific reserve in northern Siberia, is often cited as a potential testing ground for rewilding these animals to study their impact on the soil.
Will this hurt the Asian elephant surrogates? Colossal claims they are prioritizing animal welfare. The embryos are being engineered to be slightly smaller than a typical Asian elephant calf to ensure the birth is safe for the mother.
How much does this cost? Colossal Biosciences has raised over $225 million in funding from investors including Thomas Tull, Paris Hilton, and the CIA-backed venture firm In-Q-Tel. The project requires massive capital for high-level genetic engineering.